The clue in the peritoneal fluid

Researchers found something quietly interesting: women with endometriosis had lower GLP-1 levels in the fluid where the disease actually lives. It's a clue worth following — and a very long way from a treatment.

Endometriosis is a disease that lives in a specific place — the peritoneal fluid, the film that bathes the organs inside your pelvis. So when researchers went looking there and found that women with endometriosis had significantly lower GLP-1 concentrations in that fluid than women without the disease, it was the kind of finding that makes scientists lean in. The difference reached statistical significance. It's a real signal, in exactly the tissue the disease calls home.

We want to tell you about it and hold it lightly at the same time. A clue is not a cure, and the distance between "interesting biological signal" and "this will help your pain" is enormous. But the clue is genuine, and you deserve to hear about the science being done on your condition without it being either overhyped or ignored.

What patients are reporting — and its limits

Alongside the biology, a 2026 international survey out of McMaster University asked women with endometriosis what GLP-1 medications did for them. The self-reported numbers were striking: about 64.6% said at least one endometriosis-related symptom improved, and 33.7% reported at least one symptom resolving completely. The symptoms that moved most were pelvic pain, bloating, and lower back pain — three of the most stubborn, treatment-resistant complaints in the whole disease.

Now the caution, because it's the whole point. A survey captures what people report, not what a controlled trial can prove. There's no placebo group, no way to separate the medication's effect from weight loss, hope, or the ordinary ebb and flow of a symptom that flares and fades on its own. It's a strong prompt for research. It is not proof.

A lower GLP-1 level where the disease lives is a clue worth chasing. It is not a prescription.

Why researchers are curious at all

The interest isn't only about weight. Scientists looking at GLP-1s and endometriosis are circling inflammation, immune activity, scarring, and the signaling in reproductive tissue — the machinery that makes endo the whole-body, whole-life condition it is rather than a "bad period." A medication that touches inflammation in the same neighborhood where the disease inflames is, at minimum, a reasonable thing to study. That's different from a reason to prescribe.

The honest state of play

Here's where it actually stands in 2026, said plainly: no clinical trial has yet tested whether GLP-1 medications reduce endometriosis pain, shrink lesions, or improve quality of life. Some women report feeling better. The biology offers a plausible thread to pull. And that is the entire evidence base — promising fragments, not an answer. GLP-1 medications are not approved for endometriosis and are not a proven treatment for it, and we'd be doing you a disservice to imply otherwise.

What we can say without hedging is this: you deserve providers and researchers who take endometriosis seriously enough to look for its clues in the first place. For a condition that's been dismissed as "just cramps" for generations, the fact that scientists are now measuring GLP-1 in peritoneal fluid at all is its own small kind of progress. We'll keep following it — carefully, the way we follow everything.

The honest disclaimer. This is general information from the women who write Selene — not medical advice, not a recommendation, and not a promise of what will happen for you. The research described here is early and does not establish that GLP-1 medications treat endometriosis. Please make any care decision with a licensed clinician who knows your history, not with a website. Selene is editorial — we don't prescribe, sell, or dispense anything. GLP-1 medications are not a treatment for endometriosis and are not FDA-approved specifically for PMOS (PCOS).

← More from the Journal